SV Health Investors announces the appointment of Christian Jung, PhD as Partner in the Dementia Discovery Fund
Summary
His experience and proven track record in international venture capital investment and fundraising in life sciences will be invaluable to the Fund as we continue to provide investment in, and support to, innovative companies driving novel dementia research.” Christian Jung, Partner at the Dementia Discovery Fund, said: “I am delighted to join the DDF. With dementia fast becoming one of the world’s greatest health threats, DDF’s investment strategy to selectively build and back companies in this field is perfectly set to enable us to progress ground-breaking science and genuinely novel therapeutic concepts to the clinic. Since completing its fundraising in 2018, with £250 million ($350 million at the time of completion) raised from an influential group of strategic investors including industry, private, government, and impact investors, the DDF has made significant progress building a portfolio of investments in drug discovery companies and projects, predominantly in the UK and US, in four key areas including neuroimmunology, trafficking of molecules in and around cell membranes, mitochondrial health and brain synapses. Seven leading pharmaceutical companies (Biogen, Eli Lilly and Company, GSK, Johnson & Johnson, Otsuka (Astex), Pfizer and Takeda), AARP, Aegon, Bill Gates, British Patient Capital, NFL Players Association, Quest Diagnostics, UnitedHealth Group, the UK’s Department of Health and Social Care and charity Alzheimer’s Research UK among others have invested in the DDF. Heads of Neuroscience represent many of these strategic investors on the DDF Scientific Advisory Board and work closely with SV’s dedicated team of neuroscientists and experts to identify and evaluate novel approaches for the treatment of dementia.